SAP, Human, pAb

The polyclonal antibody recognizes serum amyloid P (SAP). Serum amyloid P component (SAP)
belongs to a highly conserved superfamily of calcium-dependent ligand binding and lectin
(carbohydrate binding) proteins. Due to the pentameric structure these proteins are also called
pentraxins. SAP is 25kDa in size. C-reactive protein (CRP) and SAP are well-charactarized short
pentraxins, which are produced in the liver in response to inflammatory mediators. Pentraxin 3 (PTX3)
is the prototypic long pentraxin. Both SAP and CRP are evolutionary conserved in all vertebrates and
found in distant invertebrates such as the horseshoe crab (Limulus polyphemus). They share 51%
residue sequence identity and 66% homology.
SAP is highly resistant to proteolysis, especially when it forms complexes with calcium-dependent
ligands. SAP avidly binds to macromolecular ligands, such as nucleosomal DNA, glycosaminoglycans
and amyloid fibrils. When aggregated it can bind C1q and activate the classical complement pathway.
Human SAP is not an acute phase reactant following acute stimuli, this in contrast to mouse SAP and
human CRP. In mouse, SAP levels increase significantly 24 hours after challenge with
lipopolysaccharide.
SAP is a normal plasma constituent that is present in cerebrospinal fluid (CSF), in the pathognomonic
lesions of Alzheimer’s disease (AD), cerebrovascular and intracerebral Aβ amyloid plaques and
neurofibrillary tangles. This is a result of its binding to amyloid fibrils and to paired helical filaments,
respectively. The protein itself may also be directly neurocytotoxic. SAP contributes significantly to the
pathogenesis of amyloidosis. The mechanism of its participation is not yet known and importantly may
differ between species.
The normal human serum level of SAP is 30-40 μg/ml. One study described that the mean SAP
concentration in serum of women (24 μg/ml) is significantly lower than in men (32 μg/ml). The
concentration does not alter significantly after major surgery and is only slightly increased during
chronic active diseases. Significantly low levels of SAP are only seen in patients with severe
hepatocellular impairment which reduces plasma protein synthesis. In cerebrospinal fluid (CSF), the
mean level of SAP in healthy individuals is 8.5 ng/ml